Clinical Trial Update: A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY) [Phase 2]

View source ↗

Summary

A Phase 2a, single-dose, open-label study evaluating Pegsitacianine for intraoperative fluorescence imaging to detect cancer in patients with head and neck canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer of Unknown Primary
• Head and Neck Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Pegsitacianine (Pegsitacianine)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Head and Neck Cancer, Unknown Primary Cancer | Phase 2 | Status: RECRUITING